ABSTRACT
Background: This study was aimed to investigate the hemodynamic effects of CT scan contrast media on pulse rate and blood pressure as well as identify the possible adverse drug reactions occurring after administration of contrast media.Methods: Information of patients such as age, sex, diagnosis, prescribed body part for CT scan, amount of contrast media and route of administration of contrast media were collected. Pulse and blood pressure were measured three times, before administration of iohexol or diatrizoate sodium; after 5 min and 1 hr administration of iohexol; after 1 hr and 2 hr starting of administration of diatrizoate sodium. ADR occurring after contrast media administration were observed.Results: Before Iohexol administration, SBP was 126.85±18.47 mmHg, which increased by 129.92±20.51 and 128.24±19.89 mmHg after 5 min. and 1 hr respectively after administration. Whereas before iohexol administration, DBP was 81.28±11.5 mm Hg, which was decreased by 80.58±13.03 and 78.90±13.15 mmHg after administration. The p-value for PR, pre-iohexol vs 1 hr post-iohexol was highly significant. Before Diatrizoate Sodium administration, SBP was 128.84±17.64 mmHg, that was decreased with 126.23±17.92 and 124.15±17.04 mmHg after administration. On the other hand, DBP was 81±11.99 mmHg which was decreased with 80.23±11.07 and 79.84±11.31 mmHg by Diatrizoate Sodium administration. P-value for SBP, DBP, and PR in various comparison of diatrizoate sodium administration was insignificant as well as total 18 ADRs were recorded post diatrizoate sodium and iohexol administration.Conclusions: Present study result demonstrates PR was significantly increased by administration of iohexol but not that much due to Diatrizoate Sodium especially after the 1 hr of iohexol administration. Although DBP decreased by both drugs, on the other hand, SBP increased by iohexol and decreased by Diatrizoate Sodium administration which was clinically insignificant. Although headache and giddiness were most common ADRs by both drugs.
ABSTRACT
<p>We report three cases of terminal-stage ovarian cancer where diatrizoate meglumine and diatrizoate sodium solution (Gastrografin) was effective for malignant bowel obstruction due to peritoneal dissemination. All cases had gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and constipation, showed air-fluid levels and dilation of the small intestine on imaging tests. Therefore, all the cases were diagnosed as bowel obstruction. We initiated oral administration of Gastrografin because the patients failed to show a sufficient response to other drugs such as octreotide. Their gastrointestinal symptoms such as nausea and constipation improved after administration of the drug, and they could continue oral intake. In addition, they were diagnosed as having an incomplete bowel obstruction since radiographic examination 24 hours after administration of Gastrografin confirmed its presence in the large intestine. In all the cases, Gastrografin could be used repeatedly without noticeable side effects. This study suggests that Gastrografin might be useful for evaluating bowel obstruction and improving gastrointestinal symptoms in patients with malignant bowel obstruction caused by terminal-stage ovarian cancer.</p>